First-Line SSRI for Anxiety Disorders
Sertraline (50–200 mg/day) is the first-line SSRI for adults with generalized anxiety disorder, panic disorder, or social anxiety disorder, based on the strongest evidence for efficacy, safety, favorable tolerability, and minimal drug interactions. 1, 2
Primary Recommendation
Sertraline is recommended as the preferred initial SSRI because it has demonstrated robust efficacy across multiple anxiety disorder subtypes (generalized anxiety disorder, panic disorder, social anxiety disorder, and PTSD) with FDA approval for these indications and substantial empirical support from the American Academy of Child and Adolescent Psychiatry. 1, 2
Sertraline produces significantly greater symptom reduction than placebo in generalized anxiety disorder (mean Hamilton Anxiety Scale decrease: 11.7 vs. 8.0, p<0.001) with a 63% responder rate versus 37% for placebo. 3
In social anxiety disorder, sertraline achieves a 55.6% response rate (CGI-I ≤2) versus 29% for placebo at 12 weeks, with mean Liebowitz Social Anxiety Scale reductions of -31.0 versus -21.7 (p=0.001). 4
The drug demonstrates low potential for pharmacokinetic drug interactions because it is not a potent inhibitor of cytochrome P450 isoenzymes, unlike fluoxetine, fluvoxamine, and paroxetine. 5
Alternative First-Line Option
Escitalopram (10–20 mg/day) is the preferred alternative when sertraline is not tolerated or ineffective, offering potentially fewer drug interactions than other SSRIs and the lowest risk of discontinuation syndrome. 6, 1
Escitalopram demonstrates efficacy comparable to sertraline across anxiety disorders, with number-needed-to-treat values of approximately 4.7 for social anxiety disorder and robust relapse-prevention data showing 4.04 times higher relapse risk with placebo versus escitalopram. 7
Practical Dosing Algorithm
Start with a subtherapeutic "test" dose (sertraline 25 mg daily or escitalopram 5 mg daily) to minimize initial anxiety or agitation that commonly occurs with SSRI initiation. 6, 1
Titrate sertraline by 25–50 mg increments every 1–2 weeks as tolerated, targeting 50–200 mg/day; for escitalopram, increase by 5–10 mg increments, targeting 10–20 mg/day. 6, 1
Allow adequate time for response: statistically significant improvement begins at week 2, clinically meaningful improvement occurs by week 6, and maximal benefit is achieved by week 12 or later. 6, 1, 8
Second-Tier SSRIs (Reserve for First-Line Failure)
- Paroxetine and fluvoxamine are equally effective but carry higher rates of discontinuation symptoms and greater potential for drug-drug interactions, so they should be reserved for cases where sertraline and escitalopram have failed. 6, 1
SNRI Alternative
Venlafaxine extended-release (75–225 mg/day) is an effective alternative when switching within the SSRI class is undesirable, demonstrating efficacy for generalized anxiety disorder, social anxiety disorder, and panic disorder with comparable NNT to SSRIs. 6, 8
Venlafaxine requires blood pressure monitoring due to risk of sustained hypertension, particularly at higher doses. 6
Combination with Psychotherapy
Combining sertraline or escitalopram with individual cognitive-behavioral therapy (12–20 sessions) provides superior outcomes compared with either treatment alone, with moderate-to-high strength evidence supporting this approach for moderate to severe anxiety. 6, 1, 8
Individual CBT is more clinically effective and cost-effective than group CBT for adult anxiety disorders. 6
Critical Safety Monitoring
Monitor for suicidal thinking and behavior, especially in the first months of treatment and following dose adjustments, with pooled absolute rates of 1% versus 0.2% for placebo in patients up to age 24. 6
Common side effects include nausea (the most frequent cause of discontinuation), headache, insomnia, sexual dysfunction, dizziness, and gastrointestinal symptoms; most adverse effects emerge within the first few weeks and typically resolve with continued treatment. 6, 1
Discontinue gradually to avoid withdrawal symptoms (dizziness, fatigue, headaches, nausea, anxiety), particularly with shorter half-life SSRIs like sertraline; taper over 10–14 days or longer. 1
Treatment Duration
Continue effective medication for a minimum of 9–12 months after achieving remission to prevent relapse, with reassessment monthly until symptoms stabilize, then every 3 months. 6
For recurrent anxiety episodes, long-term or indefinite maintenance therapy is advised to reduce relapse risk. 6
Medications to Avoid
Benzodiazepines should be limited to short-term (days to a few weeks) adjunctive use only due to high risk of dependence, tolerance, cognitive impairment, and withdrawal; they are not recommended as first-line or long-term therapy. 6, 8
Beta-blockers (atenolol, propranolol) are deprecated for generalized anxiety disorder and social anxiety disorder based on negative evidence from Canadian guidelines. 6